- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Teva Launches Social Media Campaign on Optimal Inhaler Use
Teva Pharmaceuticals Europe announced the launch of its Get It Right disease awareness campaign. The campaign focuses on increasing awareness and dialogue on the correct usage of asthma inhalers. It aims to challenge the public’s and physician’s min-set in managing asthma by calling attention to poor inhaler techniques while using social media and creating other media content and resources to educate people for World Asthma Day on May 2.
Using social media, the initiative is to spread the message by using hashtags #Getitright and #worldasthmaday. Additionally, a livestream broadcast will be provided to healthcare professionals on June 6, entitled Breathing New Life Into Inhalation Technology – Inside Out, An Exploration of Inhalers. The webinar will be chaired by Prof. Dr. J. Christian Virchow, Head of Department of Pneumology, University of Rostock, Germany will speak to the do’s and don’ts of inhaler techniques and how to help those affected by asthma. To register for the broadcast visit http://letstalkrespiratory.eu/inhalationtechnology
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
